111(US:YI) Jin Rong Jie·2025-05-08 13:47Core Viewpoint - 1药网 (YI) has shown a mixed financial performance with a slight decline in revenue but a significant increase in net profit, indicating potential operational efficiencies or cost management improvements [1][2]. Financial Performance - As of December 31, 2024, 1药网 reported total revenue of 14.401 billion RMB, a year-on-year decrease of 3.66% [1]. - The company achieved a net profit attributable to shareholders of -64.743 million RMB, which represents a year-on-year increase of 83.51% [1]. Company Overview - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and is a subsidiary of 111 Group [2]. - The company aims to connect patients with pharmaceuticals and medical services through digital technology, striving to create the largest healthcare platform in China [2]. - 1药网 operates various platforms including the B2C pharmaceutical platform "1药网", the internet hospital "1诊", and the B2B pharmaceutical platform "1药城", utilizing an innovative S2B2C model to integrate B-end and C-end services [2]. - The company successfully went public on NASDAQ in 2018, becoming the first Chinese internet healthcare company to list in the U.S. under the ticker "YI" [2].